Shruti Bhatt, Ph.D.
Using the novel technology, dynamic BH3 profiling (DBP), developed in the Letai lab, I am currently testing whether we can use mitochondrial priming as a platform to predict early response to targeted therapy. To directly validate this approach in vivo, I am taking patient derived xenograft models (PDX) of acute myeloid leukemia (AML) established in the Weinstock laboratory. Our hypothesis is that DBP will serve as a predictive biomarker to identify which AML patient will respond to which targeted therapy on an individual basis. A real strength of this study is that we are essentially performing chemical biology experiments and mapping pathway addiction directly on patient leukemia cells, ultimate goal of precision medicine. If successful, this would alter the paradigm of directing therapy for AML as well as other cancers.
I enjoy running on the beach, hiking, cooking and spending time with my lovely family.
Click HERE for my PubMed.